File(s) not publicly available
The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So!
journal contribution
posted on 2023-05-22, 04:20 authored by Naguy, A, Saxby PridmoreSaxby Pridmore, Alamiri, BNo single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop newer antipsychotics above and beyond DA antagonism. In this regard, authors brief on five agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.
History
Publication title
Psychopharmacology BulletinVolume
53Pagination
55-57ISSN
0048-5764Department/School
Tasmanian School of MedicinePublisher
MedWorks MediaPlace of publication
United StatesRepository Status
- Restricted